10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period. Perhaps the most surprising disappointment of all was that pharmaceutical segment revenue was flat compared with the first half of last year.
Does all of this portend dark days ahead for J&J? Not at all. In fact, the stock has risen faster than the S&P 500 so far this year. Why? Probably because smart investors recognize that the near-term future for Johnson & Johnson looks pretty bright. Here are 10 rock-solid reasons that's the case.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Aktie
106,40 €
-0,56 %
Die Merck & Co. Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Ein Kursziel von 125 € für Merck & Co. Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 106.4 €.
